Lupin Gets Tentative Approval From USFDA For Hepatitis Drugs & HIV – Dolutegravir Lamivudine is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. Whereas Tenofovir alafenamide is a medication for the treatment of chronic hepatitis B virus in adults with compensated liver disease
Indian pharma major Lupin on Friday said that it has received tentative approval from the United States Food and Drug Administration (USFDA) under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets. This product would be manufactured at Lupin’s Nagpur facility in India.
Dolutegravir Lamivudine is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. Whereas Tenofovir alafenamide is a medication for the treatment of chronic hepatitis B virus in adults with compensated liver disease.
Lupin Gets Tentative Approval From USFDA For Hepatitis Drugs & HIV
Naresh Gupta, President – of API and Global Institution Business, Lupin said, “At Lupin, we are unwavering in our commitment to providing affordable and quality treatment options for patients in low and middle-income countries. We are pleased to receive the U.S. FDA’s tentative approval of Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets, which significantly bolsters our HIV portfolio.”
Lupin’s stock was trading 1.15 percent lower on Saturday at Rs 934.85 per scrip on BSE as of 11:00 IST.
Read – Scientists working on IVG, a new reproductive method that can make human babies in labs
